Abstract
Glucocorticosteroids are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially budesonide, have been designed to achieve local effect at the site of inflammation without systemic effects of the drug. The first results of clinical trials are promising and budesonide has been shown to have an improved safety with almost comparable efficacy in comparison with prednisolone. The optimal enema dose seems to be 2 mg/100 ml at night whereas 9 mg o.m. is the optimal dose to treat ileal or right ileocolonic Crohn's disease. Topically acting GCS, like standard GCS are not effective for maintenance of remission of Crohn's disease or recurrence prevention after resection of the involved Crohn's segment.
Full Text
The Full Text of this article is available as a PDF (129.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996 Jan;110(1):45–51. doi: 10.1053/gast.1996.v110.pm8536887. [DOI] [PubMed] [Google Scholar]
- Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994 Sep 29;331(13):836–841. doi: 10.1056/NEJM199409293311303. [DOI] [PubMed] [Google Scholar]
- Löfberg R., Danielsson A., Salde L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther. 1993 Dec;7(6):611–616. doi: 10.1111/j.1365-2036.1993.tb00141.x. [DOI] [PubMed] [Google Scholar]
- Löfberg R., Rutgeerts P., Malchow H., Lamers C., Danielsson A., Olaison G., Jewell D., Ostergaard Thomsen O., Lorenz-Meyer H., Goebell H. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996 Jul;39(1):82–86. doi: 10.1136/gut.39.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., Danielsson A., Goebell H., Thomsen O. O., Lorenz-Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331(13):842–845. doi: 10.1056/NEJM199409293311304. [DOI] [PubMed] [Google Scholar]